Xenex | September 11, 2023
United States Food and Drug Administration (USFDA) has issued a De Novo authorization to Xenex Disinfection Services, Inc. (Xenex) for its LightStrikeTM+ device, an advanced high-intensity, broad-spectrum ultraviolet (UV) light robot.
The LightStrike+ devices are designed for microbial reduction on non-critical medical device surfaces in healthcare environments, following manual cleaning and disinfection practices. They are authorized for use in various healthcare settings, including unoccupied operating rooms and hospital rooms. These devices have an impressive track record, with over 1,200 healthcare facilities worldwide employing LightStrike robots for over 37 million cycles.
The new LightStrike+ device, capable of microbial reduction in as little as 2 minutes, represents the culmination of over a decade of knowledge accumulation from healthcare facilities' best practices, supported by 45 peer-reviewed studies demonstrating its safety and effectiveness, a portfolio of 193 patents, and unparalleled technical and epidemiological expertise.
Dr. Mark 'Tuck' Stibich, Xenex's Founder and Chief Scientific Officer, emphasized the long-standing collaboration with healthcare partners spanning more than a decade to enhance patient safety and public health.
As an infectious diseases epidemiologist, Dr. Stibich expressed concern about antibiotic resistance within hospital environments and the potential for FDA authorization to facilitate the broader adoption of the LightStrike+ tool in combating pathogens.
Perilous pathogens persist on surfaces within healthcare facilities, notwithstanding diligent manual cleaning endeavors. The LightStrike+ robot employs a xenon lamp to generate high-intensity pulsed UV light, which effectively diminishes the presence of these pathogens on surfaces and plays a pivotal role in interrupting the transmission chain from one patient or healthcare worker to another. Xenex's FDA authorization is substantiated by comprehensive testing conducted on more than 10,000 samples of vegetative bacteria and Clostridiodes difficile (C. diff) spores.
This authorization establishes a novel medical device product classification, with the LightStrike+ robot being its inaugural and sole product. It is a landmark in the FDA's regulatory framework for UV robots designed to diminish pathogens on non-porous, frequently touched surfaces within healthcare settings.
Furthermore, Xenex's Chief Executive Officer, Morris Miller, acknowledged the challenges hospitals face when evaluating UV technologies, citing the prevalence of unverified and exaggerated claims by some manufacturers. He underscored the significance of FDA authorization in instilling confidence among hospital decision-makers, assuring them of the accuracy and validation of Xenex's claims regarding the LightStrike+ device.
Numerous world-renowned hospitals, such as HonorHealth, Mayo Clinic, MD Anderson Cancer Center, Ochsner Health System, Stanford Health Care, and Texas Health Resources, have integrated LightStrike robots into their comprehensive disinfection strategies.
Xenex is a global leader in pioneering strategies and solutions grounded in UV technology. Its fundamental mission revolves around enabling its partners to safeguard lives and reduce human suffering by eliminating the dangerous microorganisms that cause infections. The company benefits from substantial support from renowned investors, including EW Healthcare Partners, Piper Sandler, Malin Corporation, Battery Ventures, Targeted Technology Fund II, Tectonic Ventures, and RK Ventures.
WellSky | October 13, 2023
WellSky has officially declared its acquisition of Corridor, a comprehensive technology-enabled service platform tailored to address the most formidable challenges in the post-acute care industry.
This strategic move is intended to aid care providers in enhancing their efficiency and overall performance across various domains, encompassing clinical, financial, operational, and compliance aspects. The acquisition has been facilitated through the purchase of Corridor from HealthEdge Investment Partners, a private equity firm with a dedicated focus on healthcare.
Bill Miller, CEO of WellSky, highlighted providers' need for quality care support and reduced administrative burdens. He stated,
As we looked to strengthen our services offerings, Corridor emerged as an ideal partner. Together, WellSky and Corridor help more post-acute care organizations succeed against industry challenges.
[Source – Business Wire]
Des Varady, CEO of Corridor, expressed that for over three decades, Corridor has remained dedicated to its mission of enabling clients to optimize their performance and resources through robust technology-based solutions. He conveyed his enthusiasm for Corridor's continued commitment to advancing this mission as an integral part of the WellSky team. By gaining access to WellSky's technology-driven solutions, focusing on enhancing outcomes, reducing expenses, and enhancing patient and family satisfaction, Corridor is better positioned to serve its clients more effectively.
With the integration of Corridor into its portfolio, WellSky aims to broaden its spectrum of services in medical coding and revenue cycle management.
Known for its proven software, analytics, and services, WellSky, a prominent U.S. healthcare technology company, drives better outcomes and cost savings across the healthcare and community care spectrum. It empowers providers, payers, health systems, and community organizations to streamline processes, enhance collaboration, leverage data analytics, and improve results by integrating clinical and social care.
The Corridor Group Holdings, LLC (Corridor) is a prominent post-acute healthcare sector entity offering top-tier technology-driven outsourced coding, revenue cycle, and educational solutions. It specializes in improving documentation quality and getting better client reimbursement outcomes, including for large health systems, national chains, and smaller, independently managed agencies.
Business Wire | October 31, 2023
Weave a leading all-in-one experience platform for small and medium-sized healthcare practices, today announces the addition of AI-driven voicemail transcriptions to its platform.
Now available to Weave’s 27,000+ customers, Voicemail Transcription automatically transcribes voicemails from patients allowing for efficient, visible, and private reading experiences. With this update, users will now see the voicemail transcription when they click on the Voicemail tab within their Desktop Application or within the mobile app, improving overall user experience by making it faster to consume messages without having to listen to the audio, which can often be difficult in busy settings.
said Branden Neish, Chief Product and Technology Officer at Weave.
AI has exploded in popularity over the past year, and we’re taking steps to ensure Weave is delivering state of the art offerings that empower our customers to enhance patient experiences and deliver top of the line care. AI will only continue to grow in popularity and daily use, which will have a transformative impact on the future of the healthcare industry. Weave customers that have already implemented AI into their practices claim they save an average of an hour a day with the technology.
In a new customer and consumer report conducted by Weave, the company found that patients are accepting of AI in healthcare settings and they see it leading to enhanced care and patient experiences. In fact, the majority of consumers (65%) are open to providers using AI tools in their practices. The report also found that consumers and providers are aligned with how they think AI will impact the healthcare industry, with two in three consumers (67%) and 3 in 4 (75%) healthcare providers believing that AI is likely to become a prevalent tool in healthcare.
"Artificial Intelligence is the catalyst for a new era in healthcare,” says Dr. Matt Nejad, DDS of Beverly Hills, CA. “Weave's AI-enabled voicemail transcripts are a leap in this direction, providing automation and actionable insights that empower providers to focus on what truly matters: patient care."
This announcement follows months of AI-driven activity from Weave to enhance features that allow healthcare providers to deliver quality care and improve patient experiences, including Email Assistant and Response Assistant.
Weave is a leading all-in-one customer experience platform for small- and medium-sized healthcare businesses. From the first phone call to the final invoice and every touchpoint in between, Weave connects the entire customer journey. Weave’s software solutions transform how local businesses attract, communicate with and engage customers to grow their business. In the past year, Weave has been named a G2 leader in Patient Engagement, Optometry, Dental Practice Management and Patient Relationship Management software.
Health Technology, Digital Healthcare
Aspect Imaging | September 25, 2023
Aspect Imaging, a global leader in MRI systems for neonatal patients, has been awarded an Innovative Technology contract by Vizient, the nation's largest provider -driven healthcare performance improvement company. This contract recognizes the unique qualities of Aspect Imaging's Embrace Point of Care Neonatal MRI System and its potential to bring improvements to the healthcare industry. The Embrace Point of Care Neonatal MRI System is designed specifically for the imaging needs of prematureand newborn infants, making it a critical tool in neonatal intensive care units (NICUs).
The Embrace is the world's first FDA-cleared and CE-approved MRI system for neonatal patients. It is designed to be placed directly within NICUs, overcoming the size and risk limitations associated with adult MRI scanners. The system includes features such as a temperature-controlled patient bed and a Whisper Quiet sound profile to meet the specific care needs of neonatal patients. This technology enables safer and more accessible MRI imaging for fragile neonatal patients and provides critical information to the clinical care team.
Chief Commercial Officer at Aspect Imaging, Wendy Slatery, stated,
It is an honor to have the Embrace recognized by the clinical experts at Vizient, as an Innovative Technology, and an exciting opportunity to bring valuable solutions to Vizient customers. We are looking forward to working with Vizient members seeking to expand and elevate neurocritical care of the smallest patients while reducing patient risks and staff time associated with transporting newborns to a traditional MRI. The Embrace MRI gives the neonatal medical team access to information from the life’s first hours and throughout the patient’s time in the NICU, on which critical care decisions will be based.
[Source: Business Wire]
Vizient's provider customer-led councils recommended the Embrace system for an Innovative Technology contract after evaluating its potential to enhance clinical care, patient safety, and healthcare worker safety, or improve business operations in healthcare organizations. The recognition and award of this contract highlight the potential of the Embrace Point of Care Neonatal MRI System to improve neurocritical care for the smallest patients while reducing risks associated with transporting newborns to traditional MRI facilities.
About Aspect Imaging
Aspect Imaging, a pioneering force in the field, stands as the global frontrunner in crafting and advancing compact MR imaging systems tailored for both research and clinical use. Their groundbreaking technology centers on compact, high-performance permanent magnets, introducing transformative MRI solutions to tackle unmet requirements in research and medical contexts. These innovations ensure the delivery of the finest quality images, whether at the benchtop or in point-of-care scenarios.